- Home
- /
- Treatment
- /
- Page 7
Treatments
The following database contains products that have been granted orphan status, or have been market approval in the EU or the USA.
You can filter the content by clicking on the titles: Product, Indication, Sponsor and Date. Clicking once, will filter the column alphabetically from A – Z and a second click on the same title will filter from Z – A.
Become a Partner.
Country | Product | Indication | Sponsor | Date |
---|---|---|---|---|
Salmonella Typhi strain Ty21a transfected with a plasmid vector encoding for the human vascular endothelial growth factor receptor 2 | Glioma | Vaximm GmbH;1 Julius-Hatry-Stra�e;Mannheim | August 31, 2017 | |
Venetoclax | Mantle cell lymphoma | AbbVie Inc.;1 North Waukegan Road;North Chicago, Illinois, 60064 | August 31, 2017 | |
O,O’-Bis({4-[3,5-diiodo-4-(1-methylene-1,2,3-triazol-4-ylmethoxy)phenoxy]-3,5-diiodophenyl}acetic acid)polyethylene glycol | Pancreatic Cancer | NanoPharmaceuticals, LLC;1 Discovery Place;Rensselaer, New York, 12144 | August 18, 2017 | |
Fully human monoclonal antibody specific for lymphocyte activation gene 3 and nivolumab | Metastatic Melanoma | Bristol-Myers Squibb Co.;5 Research Parkway;Wallingford, Connecticut, 06492 | August 18, 2017 | |
2-(1,1-difluoroethyl)-5-methyl-N-[4-(pentafluoro-�{6}-sulfanyl)phenyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine | Malaria | Paul Maher, MD;10644 Weymouth Street, Suite 104;Bethesda, Maryland, 20814 | August 18, 2017 | |
Humanized IgG4 Monoclonal Antibody against total complement component 1, subcomponent s (C1s) | Bullous pemphigoid | True North Therapeutics, Inc.;951 Gateway Boulevard;South San Francisco, California, 94080 | August 17, 2017 | |
Obinutuzumab | Splenic marginal zone lymphoma | Genentech, Inc.;1 DNA Way, MS 241B;South San Francisco, California, 94080 | August 17, 2017 | |
N-[2,6-bis(1-methylethyl)phenyl]-N’-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt | Congenital adrenal hyperplasia | Millendo Therapeutics, Inc.;301 North Main Street, Suite 100;Ann Arbor, Michigan, 48104 | August 17, 2017 | |
(R)-Azasetron besylate | Prevention of platinum-induced ototoxicity in pediatric patients | Sensorion SA;375, rue du Professeur Joseph Blayac;Montpellier | August 16, 2017 | |
Bitopertin | �-thalassemia | Hoffmann-La Roche Inc.;c/o Genentech, Inc., 1 DNA Way;South San Francisco, California, 94080 | August 16, 2017 | |
Upadacitinib | Still’s disease | AbbVie, Inc.;1 North Waukegan Road;North Chicago, Illinois, 60064 | August 16, 2017 | |
Nivolumab | Malignant pleural mesothelioma | Bristol-Myers Squibb Company;5 Research Parkway;Wallingford, Connecticut, 06492 | August 16, 2017 | |
Nivolumab and ipilimumab | Malignant pleural mesothelioma | Bristol-Myers Squibb Company;5 Research Parkway;Wallingford, Connecticut, 06492 | August 16, 2017 | |
Mobilized perioheral blood cells that have undergone ex-vivo negative functionial selection of GvHD-causing T-cells by short term incubation with Fas-ligand | Graft Versus Host Disease | Cellect Biotherapeutics;23 Ha'Taas Street, P.O. Box 2442;Kfar Saba | August 15, 2017 | |
Dasiglucagon | Hypoglycemia in patients with congenital hyperinsulinism (CH) | Zealand Pharma A/S;36 Smedeland;Glostrup | August 10, 2017 | |
Entospletinib | Graft Versus Host Disease | Gilead Sciences, Inc.;333 Lakeside Drive;Foster City, California, 94404 | August 10, 2017 | |
Recombinant human antibody directed against human misfolded superoxide dismutase 1 | Amyotrophic lateral sclerosis | AL-S Pharma SA;13 Wagistrasse;Schlieren | August 10, 2017 | |
Nimodipine intravenous | Treatment of subarachnoid hemorrhage | Grace Therapeutics, LLC;675 U.S. 1;North Brunswick Township, New Jersey, 08902 | August 10, 2017 | |
Cadazolid | Clostridium difficile infection in pediatric patients | Actelion Pharmaceuticals Ltd.;16 Gewerbestrasse;Allschwil | August 8, 2017 | |
Cobitolimod | Ulcerative colitis | InDex Pharmaceuticals AB;23a Tomtebodav�gen;Hagalund | August 8, 2017 | |
Nivolumab | Anal cancer | Bristol-Myers Squibb Co.;5 Research Parkway;Wallingford, Connecticut, 06492 | August 7, 2017 | |
Oxfendazole | Cysticercosis | Oxfendazole Development Group;736 Cathcart Road;Blue Bell, Pennsylvania, 19422 | August 7, 2017 | |
KIT and PDGFR inhibitor | Glioblastoma | Deciphera Pharmaceuticals, LLC;500 Totten Pond Road;Waltham, Massachusetts, 02451 | August 7, 2017 | |
Blisibimod | Patients with immunoglobulin A nephropathy | Anthera Pharmaceuticals, Inc.;25801 Industrial Boulevard, Suite B;Hayward, California, 94545 | August 7, 2017 | |
1-[4-Bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea | Glioblastoma | Deciphera Pharmaceuticals, LLC;500 Totten Pond Road;Waltham, Massachusetts, 02451 | August 7, 2017 |